Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][20]. Core Views - The company is recognized as a leading ADC platform in China, with a focus on drug pipeline value realization and key inflection points approaching [4][11]. - The core product, Lukanosatuzumab, is the second TROP2 ADC approved globally and is expected to generate significant sales in both domestic and international markets [19][42]. - The company is transitioning from a biotech firm to a comprehensive biopharmaceutical platform, with potential operational breakeven in two years [19][20]. Financial Overview - Revenue projections for 2023 to 2027 are as follows: - 2023: 1,540 million RMB - 2024: 1,933 million RMB - 2025: 2,038 million RMB - 2026: 3,004 million RMB - 2027: 4,300 million RMB - The expected CAGR for revenue from 2025 to 2027 is 45%, with product sales CAGR reaching 82% [7][20]. Product Pipeline - The company has developed approximately 20 drug candidates across three major platforms: ADC, large molecules, and small molecule targeted drugs [11][21]. - The ADC pipeline includes 11 candidates, with one approved and others in various stages of clinical development [11][27]. - The company has established significant collaborations with Merck, involving over 10 billion USD in total transaction value [11][36]. Market Potential - The global ADC market is projected to grow from 13.2 billion USD in 2024 to 115.1 billion USD by 2032, with a CAGR of 35% [21][24]. - The TROP2 ADC market in China is expected to reach 3.4 billion RMB by 2032, with a CAGR of 91.8% [42][49]. Competitive Landscape - The competitive environment for TROP2 ADCs is moderate, with opportunities for Lukanosatuzumab to gain market share against existing products [49][50]. - The company’s unique molecular design and clinical data provide a competitive edge in the ADC space [42][49].

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 1% and a transaction volume of 2.6148 million yuan, with an average daily transaction volume of 27.4616 million yuan over the past month [2] - The ETF's scale has increased by 28.6087 million yuan in the past month, ranking first among comparable funds, with a share increase of 12 million units in the last two weeks, also the highest among peers [2] - In terms of capital inflow, the ETF has seen net inflows on 5 out of the last 8 trading days, totaling 14.5271 million yuan [2] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 23.4, which is in the 4.36% percentile over the past year, indicating a valuation lower than 95.64% of the time in the past year, suggesting historical low valuations [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.09% of the index, including companies like WuXi Biologics and BeiGene [2] Group 2 - Since the reform of new drug research and development policies in 2015, China's innovative drug industry has developed a strong ecosystem, integrating excellent resources in preclinical and clinical stages, which has gained recognition from multinational corporations (MNCs) [3] - The pharmaceutical and biotechnology sector's Q1 2025 financial reports show stable revenue and profit performance, with notable improvements in certain sub-industries, indicating a return of market enthusiasm for the sector [3] - There is a recommendation to focus on international biotech companies, revaluation of innovative pipelines in generic companies, and companies in the CXO industry with significant order and operational improvements [3] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [3]

Investment Rating - The investment rating for the biopharmaceutical industry is "Positive" (maintained) [2] Core Insights - The report highlights the aggressive nature of small cell lung cancer (SCLC), with extensive stage SCLC accounting for approximately 75% of cases, which often rely on systemic treatment and have a poor prognosis [6][21] - The first-line treatment for extensive stage SCLC primarily involves PD-1/PD-L1 immunotherapy combined with doublet chemotherapy, while there are limited approved drugs for later-line treatments, indicating a significant unmet clinical need [24][30] - The report identifies three key areas of focus for research and development in the SCLC field: Antibody-Drug Conjugates (ADC), DLL3 T-cell engagers (TCE), and next-generation immune-oncology (IO) therapies [30][34] Summary by Sections 1. SCLC Overview - SCLC accounts for about 15%-20% of all lung cancer cases, with a high incidence of early metastasis [18][19] - The majority of SCLC cases are extensive stage, which has a poor prognosis and relies heavily on systemic therapies [21][22] 2. Treatment Landscape - The standard treatment for extensive stage SCLC has been established as a combination of chemotherapy and PD-1/PD-L1 immunotherapy, but the overall prognosis remains poor [24][25] - The NCCN and CSCO guidelines recommend various treatment options, including the recent inclusion of Tarlatamab as a preferred second-line treatment [28][29] 3. Research and Development Focus - ADCs are rapidly advancing in the SCLC field, targeting multiple hot spots such as B7-H3, DLL3, and TROP-2, with no ADC products currently approved for SCLC [37][38] - DLL3 TCEs, particularly Tarlatamab, have shown promising early data and are expected to reshape the treatment landscape for SCLC [30][31] - Next-generation IO therapies are being developed to challenge the current PD-L1 standard in first-line SCLC treatment [8][36] 4. Investment Recommendations - The report suggests that companies with strong pipelines in the SCLC space, such as Zai Lab, Zai Lab-U, Innovent Biologics, and others, are likely to benefit from the anticipated growth in the market as new data emerges [9]

Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

Group 1 - Company announced the sale of a large transferable certificate of deposit from Industrial Bank to Tongwei for a consideration of 52.8325 million RMB on March 21, 2025 [1] - On May 8, 2025, the company purchased a large transferable certificate of deposit from Industrial Bank for 53.0363 million RMB [1] - The total unpaid principal amount of financial products held by the company at Industrial Bank is 250 million RMB, which includes a 70 million RMB large transferable certificate of deposit and a 130 million RMB structured deposit [1] Group 2 - On May 8, 2025, the company entered into a structured deposit agreement with Zheshang Bank, agreeing to subscribe to two structured deposits, each with a principal amount of 200 million RMB [1] - The total unpaid principal amount of financial products held by the company at Zheshang Bank is 550 million RMB, including two structured deposits of 75 million RMB each and the two new structured deposits of 200 million RMB each [1] Group 3 - On May 8, 2025, the company entered into a structured deposit agreement with China Merchants Bank, agreeing to subscribe to a structured deposit with a principal amount of 100 million RMB [2] - The total unpaid principal amount of financial products held by the company at China Merchants Bank is 300 million RMB, which includes a 200 million RMB structured deposit and the new 100 million RMB structured deposit [2] Group 4 - On May 8, 2025, the company entered into a structured deposit agreement with CITIC Bank, agreeing to subscribe to a structured deposit with a principal amount of 250 million RMB [2] - The total unpaid principal amount of financial products held by the company at CITIC Bank is 400 million RMB, which includes a 150 million RMB large transferable certificate of deposit and the new 250 million RMB structured deposit [2]

Core Insights - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3] Group 1: Increased Holdings - Spring Medical (01858) saw the largest increase in holdings, up by 1.40%, bringing its total to 45.06% [2] - Yidu Tech (02158) experienced a 1.19% increase, with a new holding percentage of 20.69% [2] - Haotian International Investment (01341) increased by 1.14%, reaching a holding of 12.52% [2] - Other notable increases include Rongchang Bio (09995) at +0.65% (39.90%) and Chongqing Steel (01053) at +0.57% (27.51%) [2] Group 2: Decreased Holdings - Beijing Machinery (00187) had the largest decrease, down by 1.22% to 51.11% [2] - Hang Seng China Enterprises (02828) decreased by 0.67%, now at 0.59% [2] - First Tractor (00038) saw a reduction of 0.54%, with a holding of 51.88% [2] - Other significant decreases include Shandong Gold (01787) at -0.47% (50.26%) and Longyuan Power (00916) at -0.38% (49.85%) [2] Group 3: Five-Day Changes - Over the last five trading days, Beijing Machinery (00187) had the highest increase of 6.97%, now at 51.11% [3] - Chifeng Jilong Gold Mining (06693) increased by 6.85%, reaching 36.89% [3] - Boan Biotechnology (06955) rose by 4.29%, with a holding of 5.81% [3] - Significant decreases included Kelong Biotechnology (06990) at -3.02% (18.57%) and Hang Seng China Enterprises (02828) at -2.79% (0.59%) [3] Group 4: Twenty-Day Changes - In the last twenty days, October Rice (09676) saw the largest increase of 7.60%, now at 26.41% [4] - Dekang Agriculture (02419) increased by 4.67%, with a holding of 8.85% [4] - Yunding New Drug-B (01952) rose by 4.50%, reaching 48.80% [4] - The largest decrease was seen in Poly Property (06049) at -27.38% (21.97%) [4]

Group 1 - The Hong Kong innovative drug sector has rebounded rapidly due to a favorable external environment, with the China Securities Hong Kong Innovative Drug Index (931787) experiencing a significant recovery since its low on April 9, 2023 [1][3] - As of April 25, 2023, the index reached a peak of 979.92 points, showing a maximum cumulative increase of 37.43% from its previous low [1] - The overall increase in the Hong Kong innovative drug sector has outperformed the Hang Seng Technology Index, which has only seen a year-to-date increase of 12.48% compared to the innovative drug index's 31.03% [3] Group 2 - Recent data indicates a collective performance improvement among Hong Kong innovative drug companies, significantly exceeding market expectations [4] - In 2024, 10 out of 12 Hong Kong innovative drug companies with a market capitalization over 10 billion HKD reported positive revenue growth, with 8 companies also showing positive profit growth [4] - The company with the highest revenue growth is CloudTop New Drug-B (01952), with a revenue growth rate of 341.8%, while Innovent Biologics (01801) reported a net profit growth of 91.8% [4] Group 3 - The trend of "going global" has become a key topic, with Chinese pharmaceutical companies achieving significant growth in overseas licensing transactions [6][8] - The total transaction amount for licensing-out by Chinese pharmaceutical companies reached a historical high of 51.9 billion USD in 2024, indicating a strong global competitiveness in innovative drug development [6] - The NewCo model has emerged as a favorable strategy for domestic biotech companies, allowing for cash flow support and risk sharing in international collaborations [8] Group 4 - New industry trends in pharmaceuticals, such as weight-loss drugs, dual-antibody drugs, ADC drugs, and innovative medical devices, are expected to create new investment opportunities [9] - The Chinese government is increasing support for innovative drug exports, as evidenced by recent policies aimed at facilitating the import of research materials for biopharmaceutical companies [9] - Despite market fluctuations due to trade tensions, the pharmaceutical sector remains relatively insulated, presenting a favorable opportunity for large-scale investments [9] Group 5 - The Hong Kong innovative drug sector is poised for a valuation recovery, with significant inflows of capital from southbound investors since the beginning of the year [11] - As of April 24, 2023, net capital inflows from A-share investors into Hong Kong stocks reached 611.1 billion HKD, with healthcare becoming the second most net inflow sector [11] - The current price-to-earnings ratio (TTM) for the pharmaceutical and biotechnology sector is 27.1, indicating that the sector is undervalued compared to other growth sectors [12][13]

Investment Rating - The report assigns a "Buy" rating for Kelun Biotech, marking its first coverage with a target price of 300 HKD [1]. Core Insights - Kelun Biotech is transitioning towards an integrated model of research and sales, with its core product, SKB264 (Lukangshatuo monoclonal antibody), having received approval for two indications in China [6][18]. - The company has a robust pipeline with over 30 products in development, including 11 ADC (Antibody-Drug Conjugate) candidates that are in clinical stages [11][18]. - The partnership with MSD has led to 12 global Phase III studies for SKB264, enhancing its clinical and commercial potential [7][32]. Summary by Sections Major Data - The company operates in the pharmaceutical industry, with a total market capitalization of 63.32 billion CNY and a debt-to-asset ratio of 22.48% [1]. Financial Performance - In 2024, the company reported a revenue of 1.933 billion CNY, a year-on-year increase of 25.5%, while net losses narrowed to 267 million CNY, a 53.5% improvement from the previous year [6][16]. - The gross margin is projected to improve from 49.3% in 2023 to 80.2% by 2027, indicating a positive trend in profitability [5]. Product Pipeline - The core product SKB264 has been approved for treating 3L TNBC and 3L EGFR mutation NSCLC, with additional applications pending for 2L EGFR mutation NSCLC expected to be approved in 2025 [30][29]. - The company has established a strong ADC platform and is actively pursuing global collaborations to maximize the potential of its pipeline [11][18]. Strategic Positioning - Kelun Biotech aims to become a comprehensive pharmaceutical company through innovation, global partnerships, and self-sales capabilities, with a focus on expanding its commercial team and enhancing market access [18][6]. - The management team comprises experienced professionals from both domestic and international pharmaceutical sectors, which is expected to drive the company's long-term growth [14].

Group 1 - The core viewpoint of the article highlights the significant growth of E Fund's Hong Kong Stock Connect Quality Growth Mixed Fund C (017974), with a net asset increase of 230.89% to 287 million yuan as of March 31, 2025 [1] - The fund manager, Li Jianfeng, has an extensive background in investment banking and asset management, having worked with prestigious firms such as Goldman Sachs and UBS before joining E Fund in 2022 [1] - The fund's recent performance shows a 15.06% return over the past three months and a 29.17% return over the past year, with a cumulative return of 9.46% since inception [2] Group 2 - Recent changes in fund share scale indicate no subscriptions and minimal redemptions, with total shares remaining at 0.02 billion as of March 31, 2025, reflecting a net asset change rate of -2.54% [2] - The top ten stock holdings of the fund include Tencent Holdings, Pop Mart, Alibaba-W, China Mobile, and others, accounting for a total of 55.59% of the portfolio [2] - E Fund Management Co., Ltd. was established in April 2001, located in Zhuhai, with a registered capital of 132.442 million yuan [2]

汇添富健康生活一年持有A业绩表现较为突出。 2025年以来的震荡市场中，沪深300指数下跌3.76%，汇添富健康生活一年持有A仍保持36.03%的正收益，跑赢 业绩比较基准超过30个百分点，同类排名34/4575。 重仓股科伦博泰生物、百利天恒年内股价涨幅超四成 汇添富健康生活一年持有基金经理为张韡。公开资料显示，张韡曾任东方证券医药助理研究员，汇添富基金医 药研究员、高级医药研究员及医药行业研究组组长。 截至2025年4月23日数据（下同），该基金近一年收益率达29.23%，成立以来回报率达到16.67%，大幅跑赢业 绩比较基准及同类平均。 基金经理张韡在行业分化中抓住结构性机会，成为近年来健康主题基金的领跑者。2025年以来，基金净值累计 上涨36.03%，同类排名34/4575。 业绩领跑：年内回报达36.03% 汇添富健康生活一年持有A成立于2021年3月，基金采用自下而上的投资方法，以深入的基本面分析为立足点， 精选健康生活主题中的优质上市公司，在科学严格管理风险的前提下，谋求基金资产的中长期稳健增值。 基金业绩比较基准为中证医药卫生指数收益率*50%+中证消费服务领先指数收益率*20%+中债综合指 ...